Ultomiris Approved in the US for Adults with Generalised Myasthenia Gravis

First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce…Original Article